Introduction to the role and main efficacy of neratinib/neratinib

Neratinib/Neratinib (Neratinib) is an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor, mainly targeted at the treatment of HER2-positive breast cancer, and is especially suitable for postoperative adjuvant treatment. HER2 (human epidermal growth factor receptor 2) is a protein highly expressed on the surface of some breast cancer cells. Its overexpression can promote the growth and spread of cancer cells. The main mechanism of action of neratinib is to simultaneously inhibit the activity of HER1, HER2 and HER4 receptors, thereby blocking the signaling pathways of cancer cells, inhibiting their proliferation, and thus delaying tumor recurrence.

Unlike trastuzumab, which is a monoclonal antibody against HER2, neratinib is a small molecule targeted drug with good intracellular penetration ability. Therefore, in some patients with HER2-positive early breast cancer, especially those who still have a high risk of recurrence after completing trastuzumab treatment, neratinib can be used as a continuous oral adjuvant treatment. Its clinical use has been gradually expanded internationally, and it has been approved in some countries for the control of complex conditions such as brain metastasis, showing wider application potential.

The efficacy of neratinib is not only reflected in reducing the recurrence rate, but its ability to irreversibly inhibitHER signaling pathway also provides the possibility of long-term disease control. Especially in the mechanism by which multiple HER family receptors work together on tumor progression, the integrated blocking effect of neratinib is more in line with the development trend of modern tumor targeted therapy. Many international guidelines have included it in the recommended adjuvant treatment for HER2-positive breast cancer, providing patients with an additional treatment option during the postoperative recovery period.

Although neratinib has not yet been widely marketed in mainland China, its application in Europe and the United States provides a reference for domestic clinical practice. Its main effect is not only reflected in disease control, but also in prolonging disease-free survival and improving the overall quality of life of patients. It is an important link in the HER2 targeted treatment chain.

Reference materials:https://en.wikipedia.org/wiki/Neratinib